[Chorea, lupus and antiphospholipid antibodies].
Chorea may occur in patients with SLE with a frequency estimated at 1 to 3% in adults and up to 9% in paediatric lupus. Chorea is frequently a presenting feature, and is strongly related to the presence of antiphospholipid antibodies. A treatment with antiplatelet agents and hydroxychloroquine is generally sufficient. During follow-up, the patients with chorea have a significant higher risk to develop thrombotic events (mainly arterial). They also have an excess risk of obstetric morbidity and valvular disease. The prescription of antiplatelet agents and adequate management, especially during pregnancy, can probably reduce this risk.